Results preview: Domestic dose likely to ease US drag for pharma firms

As the Indian drug industry braces for the impact of potential US tariffs, the sector is likely to end 2024-25 with revenue growth of 11-16 per cent, said several brokerages. 

According to them, this would largely be led by domestic formulations growth as US sales are expected to see a moderate rise.

Their profit after tax (PAT) is estimated to grow in the range of 10-18 per cent. 

Nuvama Institutional Equities said therapies like antidiabetic, anti-infective and respiratory had underperformed in the Indian pharma market. 

The pharma market grew by 6 per cent in Q4FY25, while the above therapies have grown